Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pathology Oncology Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF03032345PMID 11692142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of erbB2 signal transduction pathways in human breast cancer

  2004cited by this paper
• Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53

  2001cited by this paper
• Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17β-estradiol in human breast cancer cells

  2000cited by this paper
• Expression of erbB Receptors and their Ligands in Breast Cancer: Implications to Biological Behavior and Therapeutic Response

  2000cited by this paper
• c-erbB-4 protein expression in human breast cancer

  2000cited by this paper
• Android obesity at diagnosis and breast carcinoma survival

  2000cited by this paper
• ATM heterozygosity and breast cancer: screening of 37 breast cancer patients for ATM mutations using a non-isotopic RNase cleavage-based assay

  2000cited by this paper
• Case-control differences in the reliability of reporting a history of induced abortion.

  2000cited by this paper
• NF-κB is a target of AKT in anti-apoptotic PDGF signalling

  1999cited by this paper
• NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling.

  1999cited by this paper
• Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt.

  1999cited by this paper
• Heregulin Induces Phosphorylation of BRCA1 through Phosphatidylinositol 3-Kinase/AKT in Breast Cancer Cells*

  1999cited by this paper
• Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells

  1999cited by this paper
• Heregulin regulation of Akt/protein kinase B in breast cancer cells.

  1999cited by this paper
• NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

  1999cited by this paper
• The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin

  1998cited by this paper
• HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

  1998cited by this paper
• Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Induction of sensitivity to doxorubin and etoposide by transfection of MCF-7 breast cancer cells with here β-2

  1998cited by this paper
• c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

  1998cited by this paper
• Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4

  1997cited by this paper
• Bivalence of EGF‐like ligands drives the ErbB signaling network

  1997cited by this paper
• HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

  1997cited by this paper
• Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.

  1997cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• The c-erbB3/HER3 receptor in human cancer.

  1996cited by this paper
• The c-erbB3/HER3 receptor in human cancer.

  1996cited by this paper
• Growth factors in breast cancer.

  1995cited by this paper
• Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis

  1995cited by this paper
• c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

  1994cited by this paper
• William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer.

  1993cited by this paper
• Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships.

  1993cited by this paper
• Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

  1993cited by this paper
• Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.

  1993cited by this paper
• Epidermal growth factor receptor and other oncogenes as prognostic markers.

  1992cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Expression of the ERBB3 gene product in breast cancer.

  1992cited by this paper
• Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.

  1992cited by this paper
• Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.

  1992cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

  1985cited by this paper

• PPM1G promotes the progression of lung adenocarcinoma by inhibiting p38 activation via dephosphorylation of MEK6.

  2022cites this paper
• Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

  2020cites this paper
• HER family in cancer progression: From discovery to 2020 and beyond.

  2020cites this paper
• Immediate-Early Genes and Delayed Primary Response Genes Regulated by NmU in SKBR3 HER-2 Positive Breast Cancer Cell Line

  2019cites this paper
• Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients

  2018cites this paper
• Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients

  2018cites this paper
• Clinical utility of gene-expression signatures in early stage breast cancer

  2017cites this paper
• A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

  2017cites this paper
• CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

  2017cites this paper
• Phosphorylated-p38 mitogen-activated protein kinase expression is associated with clinical factors in invasive breast cancer

  2016cites this paper
• Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients

  2016cites this paper
• Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer

  2016cites this paper
• Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies

  2016cites this paper
• CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells

  2015cites this paper
• Importance of different growth factors in oestrogen receptor-negative breast cancer

  2015cites this paper
• Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities

  2015cites this paper
• ENVIRONMEN TAL HEALTH PER SPEC T I VES ehp Parabens and Human Epidermal Growth Factor Receptor Ligands Cross-Talk in Breast Cancer Cells

  2015cites this paper
• Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells

  2015cites this paper
• Roles of p38α mitogen‐activated protein kinase in mouse models of inflammatory diseases and cancer

  2015cites this paper
• Genome-based risk prediction for early stage breast cancer.

  2014cites this paper
• The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines

  2014cites this paper
• Development of an organotypic 3D in vitro model of normal human breast tissue : a tool for cancer initiation studies

  2014cites this paper
• Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

  2014cites this paper
• Small Molecule Therapeutics Characterization of LY 2228820 Dimesylate , a Potent and Selective Inhibitor of p 38 MAPK with Antitumor Activity

  2014cites this paper
• Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies

  2014cites this paper
• Characterization of LY 2228820 dimesylate , a potent and selective inhibitor of p 38 MAPK with anti-tumor activity

  2013cites this paper
• Características patológicas asociadas al carcinoma de mama HER-2 positivo

  2013cites this paper
• An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

  2013cites this paper
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

  2012cites this paper
• Effect of HER2 status on distant recurrence in early stage breast cancer

  2012cites this paper
• Nuclear HER3 is associated with favorable overall survival in uveal melanoma

  2012cites this paper
• Generalized principles of stochasticity can be used to control dynamic heterogeneity

  2012cites this paper
• Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

  2011cites this paper
• Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

  2011cites this paper
• Estrogen Receptor/MAPK Crosstalk as a Mechanism of Radiation Resistance of Breast Cancer

  2010cites this paper
• HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival: A Study of 4046 Patients

  2010cites this paper
• Expression and function of heregulin-α and its receptors in the mouse mammary gland

  2010cites this paper
• Immunohistochemical expression of HER1, HER3, and HER4 in HER2‐positive breast cancer patients treated with trastuzumab‐containing neoadjuvant chemotherapy

  2010cites this paper
• Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort

  2009cites this paper
• Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.

  2009cites this paper
• MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer.

  2008cites this paper
• Perfil da expressão imunoistoquímica dos receptores da família ErbB e seu prognóstico em pacientes com câncer de cólon e reto com alto risco para recorrência após cirurgia radical

  2008cites this paper
• Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.

  2008cites this paper
• Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

  2008cites this paper
• Neuregulins and Cancer

  2008cites this paper
• Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.

  2007cites this paper
• Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells

  2006cites this paper
• Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

  2006cites this paper
• Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival

  2006cites this paper
• High‐level expression, activation, and subcellular localization of p38‐MAP kinase in thyroid neoplasms

  2006cites this paper
• Expression and Nuclear Localization of ErbB3 in Prostate Cancer

  2006cites this paper
• Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression.

  2006cites this paper
• Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival

  2005cites this paper
• ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter.

  2005cites this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cites this paper
• Breast cancer cells with inhibition of p38α have decreased MMP-9 activity and exhibit decreased bone metastasis in mice

  2004cites this paper
• Constants and variables in immunohistochemistry.

  2004cites this paper
• Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma

  2004cites this paper
• HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors

  2004cites this paper
• Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures

  2003cites this paper
• Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer.

  2003cites this paper
• Novel pharmacological approaches in the treatment of breast cancer

  2003cites this paper
• Molecular prognostic factors for breast cancer metastasis and survival.

  2002cites this paper